{"created":"2023-08-02T03:55:51.929731+00:00","id":4813,"links":{},"metadata":{"_buckets":{"deposit":"e7ae7714-9ee5-489e-8cff-31dd8296d7fb"},"_deposit":{"created_by":10,"id":"4813","owners":[10],"pid":{"revision_id":0,"type":"depid","value":"4813"},"status":"published"},"_oai":{"id":"oai:repository.lib.tottori-u.ac.jp:00004813","sets":["1:9","2:12","23:34:998:999"]},"author_link":["820","17322","2330","17323"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-03-28","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"65","bibliographicPageStart":"58","bibliographicVolumeNumber":"61","bibliographic_titles":[{"bibliographic_title":"Yonago Acta Medica"},{"bibliographic_title":"Yonago Acta Medica","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"【Background】 Several prognostic indices for diffuse large B-cell lymphoma (DLBCL) have been developed. Which index is appropriate for Japanese patients with DLBCL treated in real-world practice is unknown. 【Methods】 The prognostic performances of the original international prognostic index (IPI), age-adjusted IPI, National Comprehensive Cancer Network-IPI, elderly IPI and revised IPI were compared using patients with DLBCL treated in a single institute in the Yonago area in Japan. 【Results】 From 2005 through 2015, 182 patients with de novo DLBCL were treated with chemotherapy in Tottori University Hospital; 154 (85%) patients received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) although full dose was administered in 63 (35%) patients. The median age of the patients was 71 years (range 18 to 91). Three-year overall survival rate was 71.8% (95% CI, 64.1% to 78.2%). All indices significantly discriminate risk groups for overall survival of the patients (P < 0.001). Although no statistical difference of performance was found among these indices, the best scores of model fit/discrimination measures were beaten out by age-adjusted IPI, the simplest and three-factor model. 【Conclusion】 Age-adjusted IPI is still usable in real-world practice while a better predictive model is desired for Japanese patients with DLBCL.","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Tottori University Faculty of Medicine"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.33160/yam.2018.03.008","subitem_relation_type_select":"DOI"}}]},"item_10001_relation_16":{"attribute_name":"情報源","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"Yonago Acta Medica. 2018, 61(1), 58-65"}]}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"http://www.lib.tottori-u.ac.jp/yam/yam/yam61-1/61-1contents.html"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.lib.tottori-u.ac.jp/yam/yam/yam61-1/61-1contents.html","subitem_relation_type_select":"URI"}}]},"item_10001_rights_15":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Yonago Acta medica　編集委員会"}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00892882","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"05135710","subitem_source_identifier_type":"ISSN"}]},"item_10001_text_26":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_text_value":"1346-8049"}]},"item_10001_text_32":{"attribute_name":"著者所属","attribute_value_mlt":[{"subitem_text_value":"Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine / Department of Hematology, Tottori University Hospital"},{"subitem_text_value":"Department of Hematology, Tottori University Hospital"},{"subitem_text_value":"Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Hosoda, Yuzuru"},{"creatorName":"Hosoda, Yuzuru","creatorNameLang":"en"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Hino, Norihiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Motokura, Toru"},{"creatorName":"Motokura, Toru","creatorNameLang":"en"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Hino, Norihiko","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-03-26"}],"displaytype":"detail","filename":"yam61(1)_58.pdf","filesize":[{"value":"785.3 kB"}],"format":"application/pdf","licensefree":"Yonago Acta medica　編集委員会","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"yam61(1)_58.pdf","url":"https://repository.lib.tottori-u.ac.jp/record/4813/files/yam61(1)_58.pdf"},"version_id":"44caca57-82c6-4d0d-92ab-c4d185b2d6f0"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"lymphoma, large B-cell, diffuse","subitem_subject_scheme":"Other"},{"subitem_subject":"prognosis","subitem_subject_scheme":"Other"},{"subitem_subject":"rituximab","subitem_subject_scheme":"Other"},{"subitem_subject":"aged","subitem_subject_scheme":"Other"},{"subitem_subject":"Japan","subitem_subject_scheme":"Other"},{"subitem_subject":"lymphoma, large B-cell, diffuse","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"prognosis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"rituximab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"aged","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Japan","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article"}]},"item_title":"Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"10","path":["12","9","999"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2018-06-22"},"publish_date":"2018-06-22","publish_status":"0","recid":"4813","relation_version_is_last":true,"title":["Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area"],"weko_creator_id":"10","weko_shared_id":-1},"updated":"2023-09-28T23:57:22.092987+00:00"}